Adrenal gland tumor

Search Trials
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
Status:
Terminated
Last Changed:
Sep 29, 2020
First Changed:
Feb 13, 2009
Disease(s):
Neuroendocrine Tumors
Intervention(s):
RAD001erlotinib
Omics Signature in the Diagnosis of Hypertension
Status:
Unknown status
Last Changed:
Jan 26, 2017
First Changed:
May 13, 2016
Disease(s):
Hypertension
Intervention(s):
omics
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Status:
Not yet recruiting
Last Changed:
Jul 1, 2021
First Changed:
May 20, 2021
Disease(s):
Carcinoma, Renal Cell
Intervention(s):
DFF332RAD001PDR001NIR178
Evaluation of Molecular Markers in Adrenal Tumors
Status:
Terminated
Last Changed:
Nov 26, 2018
First Changed:
May 5, 2011
Disease(s):
Adrenal Gland Neoplasms
Intervention(s):
Tumor tissue biopsySurgery
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Status:
Completed
Last Changed:
Apr 28, 2017
First Changed:
Mar 2, 2007
Disease(s):
Neuroendocrine Tumors
Intervention(s):
Indium-111 pentetreotide

Connect. Empower. Inspire.